Axicabtagene ciloleucel (axi-cel), an antiCD19 CAR-T cell product with CD28 costimulatory domain in addition to CD3ζ, currently approved for treatment of relapsed diffuse large B cell lymphoma (DLBCL)and follicular lymphoma (3, 4). Here, CD28 is linked to diffuse large B-cell lymphoma.